KAUST and Industrial Clusters (IC) virtually signed a Memorandum of Understanding (MoU) to host a National BioPark project in the KAUST Research and Technology Park (KRTP). The BioPark aims to foster research and technology development in biopharmaceutical, smart health, and associated AI technologies. KAUST will provide BioPark entrepreneurs and investors access to its innovation ecosystem and facilities. Why it matters: This initiative will advance Saudi Arabia's biopharmaceutical industry and align with KAUST's focus on biological sciences, smart health, and AI, contributing to economic diversification.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
KAUST held its first bio-entrepreneurship ideation workshop, "Ignite Bio", for Biological and Environmental Science and Engineering students and postdoctoral fellows. Speakers from Noor Diagnostics and Discovery, Cellestia BioTech, Kyanos Biotechnology and SaudiVax shared their experiences about the startup journey. Saudi-based startups highlighted the need for services and products not currently available in the Kingdom, such as genetic diagnostic testing and local vaccine production. Why it matters: The workshop and the highlighted startups signal growing interest and opportunities for biotech innovation and entrepreneurship within Saudi Arabia.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.